Notice2022-09486
Prospective Grant of an Exclusive Patent License: LZK-Targeting Cancer Therapeutic
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 3, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Uereka Biosciences Inc. ("Uereka"), headquartered in East Wakefield, NH.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 85 (Tuesday, May 3, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 85 (Tuesday, May 3, 2022)]
[Notices]
[Pages 26218-26219]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-09486]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: LZK-Targeting
Cancer Therapeutic
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health (NIH), Department of Health and Human
Services (HHS), is contemplating the grant of an Exclusive Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
Notice to Uereka Biosciences Inc. (``Uereka''), headquartered in East
Wakefield, NH.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before May 18, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Jasmine Yang, Ph.D., Senior Technology Transfer
Manager, NCI Technology Transfer Center, Telephone: 301-624-8746;
Email: <a href="/cdn-cgi/l/email-protection#bcd6ddcfd1d5d2d992c5ddd2dbfcd2d5d492dbd3ca"><span class="__cf_email__" data-cfemail="88e2e9fbe5e1e6eda6f1e9e6efc8e6e1e0a6efe7fe">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
(1) HHS Ref. No.: E-163-2020-0, Entitled: Leucine Zipper-bearing Kinase
(LZK) Targeting Degraders and Methods of Use
(a) US Provisional Patent Application No.: 63/073,835 HHS Ref. No.:
E-163-2020-0-US-01 Filing Date: September 2, 2020
(b) PCT Patent Application No.: PCT/US2021/048600 HHS Ref. No.: E-
163-2020-0-PCT-02 Filing Date: September 1, 2021
(2) HHS Ref. No.: E-169-2021-0, Entitled: LZK-Targeting ATP-Competitive
Catalytic Inhibitors Suppress LZK Catalytic Activity, Inhibit MYC
Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and
Tumor Regression
(a) US Provisional Patent Application No.: 63/239,797 HHS Ref. No.:
E-169-2021-0-US-01 Filing Date: September 1, 2021
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``LZK[hyphen]targeting small molecules inhibitors or PROTACs to
treat cancers overexpressing LZK..''
Leucine-Zipper Kinase (LZK, encoded by MAP3K13, a resident gene of
the 3q amplicon) is highly expressed in the mouse brain, particularly
the cerebellum, but also in the intestine, olfactory bulb, liver, and
kidney and shown to promote neurite growth. In addition, LZK
overexpression and 3q amplification is associated with cancer such as
squamous cell carcinomas (SCC). The Intellectual Property are directed
to compositions of matter to LZK kinase inhibitors as well as the
combination of a LZK binding moiety to an E3-ligase binding moiety via
a linker and specific structures to each component as well as methods
of using said compositions to treat LZK
[[Page 26219]]
overexpression diseases and condition and to degrade or inhibit LZK
activity.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published Notice, the National
Cancer Institute receives written evidence and argument establishing
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially and may be made
publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 28, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-09486 Filed 5-2-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 3, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.